Zikuan Leng, MD, PhD

Biography

Dr. Zikuan Leng is a renowned orthopaedic surgeon and translational researcher at The First Affiliated Hospital of Zhengzhou University, China. His clinical expertise centers on spinal cord injury management, while his research focuses on stem cell therapy, especially exploring the therapeutic potential of Multilineage-differentiating Stress-Enduring (Muse) cells for regenerative medicine and neurorestorative therapies. Dr. Leng has also contributed to cell-based therapies for infectious diseases, such as COVID-19, and investigates bone disease mechanisms, including osteonecrosis of the femoral head. Selected Publications “Transplantation of ACE2-Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia” Aging and Disease, 2020; 11(2):216-228 Demonstrated that ACE2-overexpressing MSC transplantation is a safe and promising treatment for critically ill COVID-19 patients, improving clinical outcomes. (PMC) “Quantitative Analysis of SSEA3+ Cells from Human Umbilical Cord after Magnetic Sorting” Cell Transplantation, 2019; 28(4):513-521 Established an efficient protocol for isolating and expanding SSEA3+ Muse cells from the human umbilical cord, facilitating their potential clinical application in regenerative medicine. (ResearchGate, Semantic Scholar) “Pathological Mechanisms and Related Markers of Steroid-Induced Osteonecrosis of the Femoral Head” Annals of Medicine, 2024; 56(1):e2416070 Investigated the complex pathophysiology of steroid-induced osteonecrosis, highlighting mechanisms like impaired osteogenesis, lipid accumulation, increased intraosseous pressure, and vascular disruption. (PubMed) Conclusion Dr. Zikuan Leng’s work contributes significantly to the advancement of stem cell therapies, spinal cord injury treatment, and orthopaedic regenerative medicine. His research bridges basic science and clinical translation, providing innovative therapies for neurological, orthopedic, and systemic conditions.